Home > Newsletters > Drug Industry Daily > As FDA Dawdles on Biosimilar Interchangeability, One Expert Questions Whether It’s Achievable
Drug Industry Daily
Aug. 10, 2012 | Vol. 11 No. 157
As FDA Dawdles on Biosimilar Interchangeability, One Expert Questions Whether It’s Achievable
Companies blazing a path in the biosimilars arena likely have a long wait before their products can achieve an interchangeability designation, as the FDA admits to slow progress on that standard.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.